PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO ...
Q1 2026
May 12, 2026
FY 2025
Mar 4, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 7, 2025
